Sildenafil Citrate
A gold-standard, FDA-approved PDE5 inhibitor formulated to treat Erectile Dysfunction (ED) by enhancing penile blood flow under expert urological guidance.
Clinical Highlights
- Targeted Vasodilation: Inhibits PDE5 enzymes to elevate cGMP levels and promote smooth muscle relaxation.
- Proven Efficacy: The most extensively researched first-line oral therapy for male erectile restoration.
- Specialist Care: Prescribed following tailored cardiovascular and hormonal health assessments.
Mechanism of Action & Clinical Dosage
Pharmacological principles, physiological pathway, and dosage guidelines for the medical management of Erectile Dysfunction (ED).
Mechanism of Action
Selective PDE5 Inhibition
Sildenafil acts as a potent and selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in the corpus cavernosum.
Nitric Oxide Pathway Activation
During sexual stimulation, local release of Nitric Oxide (NO) activates guanylate cyclase, increasing cGMP levels and resulting in smooth muscle relaxation and enhanced arterial blood flow.
Pharmacokinetics & Metabolism
Rapidly absorbed with peak plasma concentrations reached within 30 to 120 minutes. Extensively metabolized by hepatic enzymes (primarily CYP3A4 and CYP2C9) with a terminal half-life of 3 to 5 hours.
Clinical Dosage Guidelines
Initial Recommended Dose
Administered orally approximately 1 hour prior to anticipated sexual activity. Taken on an empty stomach for optimal plasma absorption rate.
Reduced Dose Titration
Recommended for elderly patients (>65 years), individuals with mild-to-moderate hepatic/renal impairment, or patients co-administered with CYP3A4 inhibitors.
Maximum Recommended Dose
Based on clinical efficacy and patient tolerance. Strictly limited to a maximum frequency of once per 24-hour period under medical supervision.
Contraindications & Watchful Side Effects
Clinical safety considerations, adverse reaction monitoring, and critical drug-drug contraindications for Sildenafil therapy.
| Absolute Contraindications | Strictly co-administration is prohibited with organic nitrates (e.g., Nitroglycerin, Isosorbide mononitrate/dinitrate) or soluble guanylate cyclase (sGC) stimulators (e.g., Riociguat). Concurrent use causes potentiation of vasodilatory effects leading to severe, life-threatening hypotension. |
|---|---|
| Watchful Warnings & Precautions |
Requires careful urological and cardiovascular evaluation in patients with:
|
| Common Adverse Effects |
Generally transient and mild-to-moderate in severity:
Headache (16%)
Facial Flushing (10%)
Dyspepsia / Indigestion (7%)
Nasal Congestion (4%)
Cyanopsia / Blue Tinted Vision (3%)
Dizziness (2%)
|
| Medical Emergencies |
Immediate medical intervention is required if experiencing:
|
| Key Drug Interactions |
Alpha-Blockers: Concomitant use with drugs like Tamsulosin or Doxazosin may cause symptomatic hypotension; titrate carefully. CYP3A4 Inhibitors: Ketoconazole, Erythromycin, and Ritonavir significantly increase Sildenafil plasma concentrations. A lower starting dose (25 mg) is indicated. |
Comparing Sildenafil with Alternative ED Therapies
An evidence-based comparison evaluating Sildenafil (50mg/100mg) against Tadalafil, intracavernosal Alprostadil injections, and restorative shockwave therapy (Li-ESWT).
| Clinical Parameter | Sildenafil On-Demand 50mg / 100mg (Episodic) | Tadalafil On-Demand 10mg / 20mg (Episodic) | Tadalafil Daily 2.5mg / 5mg (Once Daily) | Alprostadil (ICI) Intracavernosal Injection | Li-ESWT Low-Intensity Shockwave |
|---|---|---|---|---|---|
| Therapeutic Window | 4 – 6 hours (Short, highly defined duration) | Up to 36 hours ("The Weekend Pill") | Continuous 24/7 coverage (after 3–5 days) | Predictable (approx. 30–60 minutes) | Long-term disease-modifying effect (not acute) |
| Onset of Action | 30 – 60 minutes post-ingestion | 30 – 45 minutes post-ingestion | Steady-state maintained after 3–5 days | Rapid (5 – 15 minutes) post-injection | Cumulative results over 6–12 clinical sessions |
| Food Dependency | Best taken on an empty stomach; high-fat meals delay and decrease absorption | Unaffected by food or high-fat meals | Unaffected by food or meal timing | No meal interactions | No meal interactions |
| Peak Erection Hardness | Very High (Peak Hardness); strong efficacy during the active 4-hour window | Consistent, steady, and sustained | Natural, steady baseline response | Highest & Most Reliable; direct vascular smooth muscle relaxation | Gradual improvement in natural baseline rigidity |
| Side Effect Profile | Headache, facial flushing, dyspepsia, transient blue vision/cyanopsia (PDE6 effect) | Headache, nasal congestion, muscle aches/myalgia, dyspepsia | Lower incidence rate of mild headache or dyspepsia | Penile pain, localized hematoma, risk of priapism | Mild local discomfort during treatment; zero systemic side effects |
| Clinical Legacy & Cost | Most cost-effective; longest clinical trial history and global safety track record (>25 years) | Slightly higher cost per tablet | Higher cumulative cost due to daily administration | Higher cost; requires self-injection training & supplies | Higher initial investment per therapy protocol |
The First-Line Gold Standard for Peak Hardness
Backed by over 25 years of worldwide clinical data, Sildenafil remains the benchmark for fast-acting, high-rigidity results when intimacy is planned within a defined 4- to 6-hour window.
Take on an Empty Stomach for 100% Efficacy
Unlike Tadalafil, high-fat meals severely impair Sildenafil's absorption rate. For maximum potency and faster onset, take your dose on an empty stomach or at least 1–2 hours after light meals.
Short & Focused Duration vs. 36-Hour Coverage
Sildenafil is ideal for men who prefer a medication that clears the body quickly without remaining in the system for days. If you prefer long weekend windows without scheduling around meals, Tadalafil is the preferred alternative.
Options for PDE5i Non-Responders
If maximum-dose Sildenafil (100mg) fails to produce an erection, Alprostadil (ICI) bypasses damaged cavernous nerves entirely to deliver reliable rigidity, while Li-ESWT helps rehabilitate microvascular flow.
Clinical References & Guidelines
Peer-reviewed medical literature, official regulatory monographs, and international clinical guidelines supporting Sildenafil administration.
Regulatory & Urological Monographs
4 Key Literature Sources-
01
U.S. Food and Drug Administration (FDA)
Viagra (sildenafil citrate) Tablets: Full Prescribing Information. FDA Center for Drug Evaluation and Research (CDER). Revised October 2020. Reference ID: 4125892.
-
02
European Association of Urology (EAU)
Salonia A, et al. EAU Guidelines on Sexual and Reproductive Health. European Association of Urology Guidelines Office, Arnhem, The Netherlands. Edition 2024.
-
03
American Urological Association (AUA)
Burnett AL, et al. Erectile Dysfunction: AUA Guideline. The Journal of Urology. 2018;200(3):633-641. DOI: 10.1016/j.juro.2018.05.004.
-
04
European Medicines Agency (EMA)
European Public Assessment Report (EPAR): Viagra (sildenafil). Summary of Product Characteristics (SmPC). EMA/521481/2021.